Abstract: Ring deuterated gaboxadol is provided. The ring deuterated gaboxadol is useful in the treatment of psychiatric disorders and is more effective than non-deuterated gaboxadol in such treatments. Deuterated gaboxadol is useful in combinations with other compounds to provide additive and synergistic effects for patient therapies. In a specific embodiment, the deuterated gaboxadol is d6-gaboxadol.

Abstract: Ring deuterated gaboxadol is provided. The ring deuterated gaboxadol is useful in the treatment of psychiatric disorders and is more effective than non-deuterated gaboxadol in such treatments. Deuterated gaboxadol is useful in combinations with other compounds to provide additive and synergistic effects for patient therapies. In a specific embodiment, the deuterated gaboxadol is d6-gaboxadol.

Abstract: Ring deuterated gaboxadol is provided. The ring deuterated gaboxadol is useful in the treatment of psychiatric disorders and is more effective than non-deuterated gaboxadol in such treatments. Deuterated gaboxadol is useful in combinations with other compounds to provide additive and synergistic effects for patient therapies. In a specific embodiment, the deuterated gaboxadol is d6-gaboxadol.

Abstract: Methods and compositions are disclosed for rapidly reducing the risk of suicide in patients suffering from acute suicidality and rapidly relieving mood symptoms in major depression and treatment-resistant depression using a novel therapeutic regimen comprising a single or intermittent administration of a high dose of gaboxadol, or a pharmaceutically acceptable salt thereof, to the subject in need thereof.

Abstract: Methods and compositions are disclosed for rapidly reducing the risk of suicide in patients suffering from acute suicidality and rapidly relieving mood symptoms in major depression and treatment-resistant depression using a novel therapeutic regimen comprising a single or intermittent administration of a high dose of gaboxadol, or a pharmaceutically acceptable salt thereof, to the subject in need thereof.

Abstract: This disclosure reports on the discovery that low dose lithium can act in synergy with gaboxadol to enhance lithium's action on brain signaling activity. This combination of lithium and gaboxadol may greatly reduce the amount of lithium needed to treat many debilitating psychiatric disorders, such as bipolar disorder, depression, treatment resistant depression and suicidality, while reducing the often-serious side effects associated with high dose and chronic lithium treatment, especially nephrotoxicity, nephrogenic diabetes insipidus and chronic kidney disease. Co-administration of gaboxadol and lithium may also be useful for the treatment of refractory bipolar disorder, i.e. bipolar disorder which cannot be treated appropriately by administration of lithium alone. Gaboxadol may also prove useful as add-on therapy for the augmentation of the response to lithium in patients that do not respond to conventional lithium monotherapy.

Abstract: Methods and compositions are disclosed for rapidly reducing the risk of suicide in patients suffering from acute suicidality and rapidly relieving mood symptoms in major depression and treatment-resistant depression using a novel therapeutic regimen comprising a single or intermittent administration of a high dose of gaboxadol, or a pharmaceutically acceptable salt thereof, to the subject n need thereof.

Abstract: Methods and compositions are disclosed for rapidly reducing the risk of suicide in patients suffering from acute suicidality and rapidly relieving mood symptoms in major depression and treatment-resistant depression using a novel therapeutic regimen comprising a single or intermittent administration of a high dose of gaboxadol, or a pharmaceutically acceptable salt thereof, to the subject n need thereof.

Abstract: Methods and compositions are disclosed for rapidly reducing the risk of suicide in patients suffering from acute suicidality and rapidly relieving mood symptoms in major depression and treatment-resistant depression using a novel therapeutic regimen comprising a single or intermittent administration of a high dose of gaboxadol, or a pharmaceutically acceptable salt thereof, to the subject n need thereof.

Abstract: An exemplary system and method for imaging tissue includes using an illumination objective, directing one or multi photon excitation lights onto a portion of a tissue from a position on top and at an oblique angle relative to the tissue while the tissue is mounted on a stage. The method further includes generating a tissue-penetrating light-sheet from the one or multi photon excitation lights. Using a detection objective, the method detects the tissue-penetrating light-sheet. Upon detecting the tissue-penetrating light-sheet, it uses the detection objective, to collect fluorescent signals from the tissue and uses the fluorescent lights to acquire a first image of the tissue while the tissue is an imaging position. A second image of the tissue is acquired while the tissue is in the imaging position. The first and second images each defined by first and second data, respectively.

Abstract: Described herein are methods of screening drugs in a non-human animal using high resolution technology leading to generation of pharmacomaps. Further described herein are methods of predicting the therapeutic benefit and/or toxicity of drug candidate compounds. In specific embodiments, provided herein are methods of predicting the clinical effects of a test drug based on comparison of the pharmacomap of the test drug to the pharmacomap of one or more reference drugs with known clinical outcomes.